Reproducibility in preclinical and animal experimentation – EATRIS Webinar series (3/6)Join event
|Date & Time||December 13 2019, 14:00 – 15.00 CET|
- Björn Gerlach (PAASP)
- Michael Raess (INFRAFRONTIER)
This webinar will address the issues of unreproducible data of in vivo experiments in preclinical research and point towards potential causes. The webinar will introduce the IMI project EQIPD (European Quality in Preclinical Data), which aims to set-up a lean and fit-for-purpose quality system for preclinical research. In the second part of the webinar INFRAFRONTIER, the European Research Infrastructure for the generation, phenotyping, archiving and distribution of model mammalian genomes, will illustrate how its partners across Europe work together to provide open access to a unique, standardised, high quality resource for basic and preclinical biomedical research.
An interactive Q&A session will conclude this 60-minute-webinar.
Reproducibility is a foundational element of the scientific method, a benchmark upon which the reliability of an experiment can be tested. However, the field is facing alarmingly high irreproducibility rates as illustrated in various industry publications, with reports ranging from 50% to 80% of published results not being reproducible. It has been estimated that in the US alone, $28B in funding is spent on preclinical research that is not reproducible. This estimation does not even consider the impact on delaying translational research and causing high failure rates observed for the development of new treatments.
In this context, EATRIS will run a series of webinars this fall, looking at reproducibility issues experienced during specific phases of the drug development pipeline (screening, preclinical models, biomarker development & analytical platforms, clinical validation). The aim is to bring best practices together and to discuss solutions designed to tackle the identified bottlenecks.
You will have the chance to get the latest updates from experts in the field as well as participate in a Q&A session at the end of the lecture. Please note that you will have the opportunity to watch again later as all webinars will be recorded.